to treat polymyositis and dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the recent Orphan Drug Designation for Restem-L in IIM. . Emerging ...

Researchers have discovered that serum from myositis patients directly affects ... Serum from patients with idiopathic inflammatory myopathy induces skeletal muscle weakness, Annals of the ...

program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). This is the second regulatory ...

program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). This is the second regulatory ...